{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:09:07Z","timestamp":1778296147484,"version":"3.51.4"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ctrv.2026.103139","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:33:59Z","timestamp":1776814439000},"page":"103139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Expanding the therapeutic Frontier: Liver transplantation for unresectable colorectal liver metastases"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-0499","authenticated-orcid":false,"given":"Alex B.","family":"Munster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umair","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Imber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan","family":"Bhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-6182","authenticated-orcid":false,"given":"Khurum","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103139_b0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2026.103139_b0010","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2026.103139_b0015","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103139_b0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12957-019-1771-9","article-title":"Synchronous and metachronous liver metastases in patients with colorectal cancer-towards a clinically relevant definition","volume":"17","author":"Engstrand","year":"2019","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0025","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejca.2016.09.028","article-title":"Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review","volume":"69","author":"Goey","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0030","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/bjs5.50299","article-title":"Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study","volume":"4","author":"V\u00e4yrynen","year":"2020","journal-title":"BJS Open"},{"key":"10.1016\/j.ctrv.2026.103139_b0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.dld.2024.06.018","article-title":"Trends in incidence of infrequent and frequent synchronous metastases from colorectal cancer","volume":"57","author":"Jooste","year":"2025","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ctrv.2026.103139_b0040","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2340\/1651-226X.2025.42985","article-title":"Synchronous metastases from colorectal cancer. Treatment and long-term survival compared to patients with metachronous metastases: a population-based study from Central Norway 2001-2015","volume":"64","author":"Storli","year":"2025","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00384-014-2085-6","article-title":"Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands","volume":"30","author":"Elferink","year":"2015","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.ctrv.2026.103139_b0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/1878-0261.12018","article-title":"Determinants of metastatic competency in colorectal cancer","volume":"11","author":"Tauriello","year":"2017","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0055","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1186\/1471-2407-14-810","article-title":"Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma","volume":"14","author":"Hackl","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0060","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","article-title":"Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases","volume":"32","author":"van der Geest","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ctrv.2026.103139_b0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/jgh.12685","article-title":"Incidence and survival in late liver metastases of colorectal cancer","volume":"30","author":"Landreau","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103139_b0070","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","article-title":"Colorectal cancer liver metastases - a population-based study on incidence, management and survival","volume":"18","author":"Engstrand","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0075","first-page":"496","article-title":"The clinical correlation of an autopsy study of recurrent colorectal cancer","volume":"189","author":"Welch","year":"1979","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0080","first-page":"283","article-title":"Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors","volume":"4","author":"Kanas","year":"2012","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ctrv.2026.103139_b0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.sla.0000217629.94941.cf","article-title":"Epidemiology and management of liver metastases from colorectal cancer","volume":"244","author":"Manfredi","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0090","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1245\/s10434-006-9215-5","article-title":"Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis","volume":"14","author":"Tsai","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0095","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1200\/JCO.2011.36.4414","article-title":"Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results\u2013Medicare data","volume":"29","author":"Weiss","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0100","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s12885-016-2412-0","article-title":"Better survival in right-sided versus left-sided stage I - III colon cancer patients","volume":"16","author":"Warschkow","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000443644","article-title":"Right Sided Colon Cancer as a Distinct Histopathological Subtype with Reduced Prognosis","volume":"33","author":"Nitsche","year":"2016","journal-title":"Dig Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0110","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cncr.29129","article-title":"Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?","volume":"121","author":"Price","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0115","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.ejso.2016.04.002","article-title":"Right colon cancer: Left behind","volume":"42","author":"Gervaz","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1463-1318.2010.02539.x","article-title":"Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series","volume":"14","author":"van der Pool","year":"2012","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.ctrv.2026.103139_b0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2015.10.055","article-title":"Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study","volume":"53","author":"Nor\u00e9n","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0130","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(94)92529-1","article-title":"Factors influencing the natural history of colorectal liver metastases","volume":"343","author":"Stangl","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103139_b0135","first-page":"202","article-title":"Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab","volume":"6","author":"Yoo","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0140","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ejca.2006.04.012","article-title":"Towards a pan-European consensus on the treatment of patients with colorectal liver metastases","volume":"42","author":"Van Cutsem","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000454697","article-title":"Thermal Ablation in the Management of Colorectal Cancer Patients with Oligometastatic Liver Disease","volume":"33","author":"Petre","year":"2017","journal-title":"Visc Med"},{"key":"10.1016\/j.ctrv.2026.103139_b0150","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1245\/s10434-014-3817-0","article-title":"A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases","volume":"21","author":"Correa-Gallego","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0155","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jvir.2014.04.007","article-title":"Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system","volume":"25","author":"Hosein","year":"2014","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.ctrv.2026.103139_b0160","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1200\/JCO.2007.12.1764","article-title":"Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?","volume":"25","author":"Mocellin","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0165","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1148\/radiol.2501080295","article-title":"Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study","volume":"250","author":"Vogl","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/j.ctrv.2026.103139_b0170","first-page":"4581","article-title":"Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead\u00ae, drug-eluting bead loaded with irinotecan: results of a phase II clinical study","volume":"31","author":"Aliberti","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2026.103139_b0175","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0180","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.radonc.2018.06.035","article-title":"Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review","volume":"129","author":"Petrelli","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0185","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/SLA.0000000000000786","article-title":"Chemotherapy or Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer?","volume":"261","author":"Dueland","year":"2015","journal-title":"Annals of Surgery"},{"key":"10.1016\/j.ctrv.2026.103139_b0190","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/curroncol31020080","article-title":"Liver Transplantation for Unresectable Colorectal Liver Metastasis: Perspective and Review of Current Literature","volume":"31","author":"Robinson","year":"2024","journal-title":"Current Oncology"},{"key":"10.1016\/j.ctrv.2026.103139_b0195","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1477-2574.2012.00451.x","article-title":"Resectability of colorectal liver metastases: an evolving definition","volume":"14","author":"Rocha","year":"2012","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ctrv.2026.103139_b0200","doi-asserted-by":"crossref","DOI":"10.1177\/15330338251361238","article-title":"Liver Transplantation for Unresectable Colorectal Liver Metastases","volume":"24","author":"Kadakia","year":"2025","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103139_b0205","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae367","article-title":"Liver transplantation for colorectal cancer with liver metastases","volume":"30","author":"Ueberroth","year":"2025","journal-title":"The Oncologist"},{"key":"10.1016\/j.ctrv.2026.103139_b0210","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3390\/cancers15072113","article-title":"Pushing the Limits of Surgical Resection in Colorectal Liver Metastasis: How Far Can We Go?","volume":"15","author":"Calderon Novoa","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103139_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.109728","article-title":"Liver metastases from colorectal cancer: A joint ESSO\u2013EAHPBA\u2013UEMS core curriculum collaboration","volume":"51","author":"Carrion-Alvarez","year":"2025","journal-title":"European Journal of Surgical Oncology"},{"key":"10.1016\/j.ctrv.2026.103139_b0220","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1432-2277.2010.01097.x","article-title":"Liver transplantation for colorectal liver metastases: revisiting the concept: Liver transplantation for colorectal liver metastases","volume":"23","author":"Foss","year":"2010","journal-title":"Transplant International"},{"key":"10.1016\/j.ctrv.2026.103139_b0225","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/SLA.0b013e3182823957","article-title":"Liver transplantation for nonresectable liver metastases from colorectal cancer","volume":"257","author":"Hagness","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0230","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1200\/JCO.2011.38.0915","article-title":"Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study","volume":"30","author":"Tveit","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0235","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/SLA.0000000000003404","article-title":"Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases","volume":"271","author":"Dueland","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0245","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2023.2932","article-title":"Long-Term Survival, Prognostic Factors, and Selection of Patients With Colorectal Cancer for Liver Transplant: A Nonrandomized Controlled Trial","volume":"158","author":"Dueland","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0250","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2020.08.015","article-title":"Liver transplantation for secondary liver tumours: The difficult balance between survival and recurrence","volume":"73","author":"Line","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.ctrv.2026.103139_b0255","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1245\/s10434-013-3449-9","article-title":"Patterns of Recurrence After Liver Transplantation for Nonresectable Liver Metastases from Colorectal Cancer","volume":"21","author":"Hagness","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0260","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00259-017-3843-9","article-title":"The prognostic value of 18F\u2013FDG PET\/CT prior to liver transplantation for nonresectable colorectal liver metastases","volume":"45","author":"Grut","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctrv.2026.103139_b0265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s13193-023-01827-4","article-title":"Liver Transplantation for Nonresectable Colorectal Liver Metastases (CRLM)","volume":"15","author":"Malik","year":"2024","journal-title":"Indian J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0270","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(24)01595-2","article-title":"Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial","volume":"404","author":"Adam","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.ctrv.2026.103139_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102608","article-title":"Safety and feasibility of chemotherapy followed by liver transplantation for patients with definitely unresectable colorectal liver metastases: insights from the TransMet randomised clinical trial","volume":"72","author":"Adam","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ctrv.2026.103139_b0280","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.surg.2018.04.039","article-title":"Early mortality after liver transplantation: Defining the course and the cause","volume":"164","author":"Baganate","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2026.103139_b0285","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","article-title":"Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)","volume":"57","author":"Adam","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103139_b0290","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamasurg.2022.0300","article-title":"Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases","volume":"157","author":"Hernandez-Alejandro","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0295","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jamasurg.2024.2057","article-title":"Progression-Free Survival for Liver Transplant vs Alternative Therapy in Unresectable Colorectal Liver Metastasis","volume":"159","author":"Byrne","year":"2024","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0300","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/codi.16446","article-title":"the NHS Blood and Transplant Liver Transplantation for Colorectal Liver Metastases Fixed Term Working Unit. United Kingdom criteria for liver transplantation in the setting of isolated unresectable colorectal liver metastases","volume":"25","author":"Murphy","year":"2023","journal-title":"Colorectal Disease"},{"key":"10.1016\/j.ctrv.2026.103139_b0305","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.hpb.2023.02.011","article-title":"Liver transplantation for isolated unresectable colorectal liver metastases - Protocol for a service evaluation in the United Kingdom - UKCoMET study","volume":"25","author":"Menon","year":"2023","journal-title":"HPB"},{"key":"10.1016\/j.ctrv.2026.103139_b0310","doi-asserted-by":"crossref","first-page":"e1026","DOI":"10.1097\/SLA.0000000000005803","article-title":"The High Incidence of Occult Carcinoma in Total Hepatectomy Specimens of Patients Treated for Unresectable Colorectal Liver Metastases With Liver Transplant","volume":"278","author":"Ch\u00e1vez-Villa","year":"2023","journal-title":"Annals of Surgery"},{"key":"10.1016\/j.ctrv.2026.103139_b0315","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/livers5030044","article-title":"Liver Transplantation for Colorectal Liver Metastasis: A Comprehensive Review of Current Practices and Future Trends","volume":"5","author":"Tariq","year":"2025","journal-title":"Livers"},{"key":"10.1016\/j.ctrv.2026.103139_b0320","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1186\/s13063-022-06778-9","article-title":"SOULMATE: the Swedish study of liver transplantation for isolated colorectal cancer liver metastases not suitable for operation or ablation, compared to best established treatment-a randomized controlled multicenter trial","volume":"23","author":"Reivell","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.ctrv.2026.103139_b0325","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3138\/canlivj-2025-0014","article-title":"The emerging role of liver transplantation in metastatic colorectal cancer","volume":"8","author":"Rafael","year":"2025","journal-title":"Can Liver J"},{"key":"10.1016\/j.ctrv.2026.103139_b0330","first-page":"250","article-title":"Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial)","volume":"22","author":"Sposito","year":"2023","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0335","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41416-023-02213-1","article-title":"Liver transplantation in metastatic colorectal cancer: are we ready for it?","volume":"128","author":"Ros","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12957-018-1549-5","article-title":"Living donor liver transplantation with two-stage hepatectomy for patients with isolated, irresectable colorectal liver-the LIVER-T(W)O-HEAL study","volume":"17","author":"Rauchfu\u00df","year":"2019","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0345","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1016\/j.hpb.2023.07.247","article-title":"Technical Refinements to the RAPID Technique for Unresectable Colorectal Liver Metastases","volume":"25","author":"Cillo","year":"2023","journal-title":"HPB"},{"key":"10.1016\/j.ctrv.2026.103139_b0350","doi-asserted-by":"crossref","unstructured":"Maspero M, Sposito C, Virdis M, Citterio D, Pietrantonio F, Bhoori S, et al. Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues. Cancers (Basel) 2023;15. 10.3390\/cancers15020345.","DOI":"10.3390\/cancers15020345"},{"key":"10.1016\/j.ctrv.2026.103139_b0355","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2468-1253(21)00219-3","article-title":"Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines","volume":"6","author":"Bonney","year":"2021","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.ctrv.2026.103139_b0360","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1007\/s00259-021-05190-w","article-title":"Letter to the Editor: It is time for the nuclear medicine community to define a unit for the total lesion glycolysis (TLG) and similar metrics","volume":"48","author":"Duarte","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctrv.2026.103139_b0365","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00259-021-05613-8","article-title":"Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF)","volume":"49","author":"Beauregard","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctrv.2026.103139_b0370","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0375","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of Metastatic Colorectal Cancer: ASCO Guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0380","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.7111","article-title":"Revisiting the Association of ECOG Performance Status With Clinical Outcomes in Diverse Patients With Cancer","volume":"22","author":"Kumar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2026.103139_b0385","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0390","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0395","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103139_b0400","first-page":"133","article-title":"FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data","volume":"18","author":"Neugut","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0405","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0410","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.critrevonc.2017.08.006","article-title":"Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis","volume":"118","author":"Marques","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2026.103139_b0415","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103139_b0420","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103139_b0425","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103139_b0430","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103139_b0435","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0440","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ijc.28955","article-title":"Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer","volume":"136","author":"Schirripa","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0445","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","article-title":"Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis","volume":"51","author":"Pietrantonio","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0450","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","article-title":"Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial","volume":"11","author":"Folprecht","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0455","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.19.01340","article-title":"FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)","volume":"37","author":"Modest","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0460","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0465","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1470-2045(19)30798-3","article-title":"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Bridgewater","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0470","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-2407-12-89","article-title":"Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups","volume":"12","author":"Macedo","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0475","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0480","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103139_b0485","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdu580","article-title":"Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial","volume":"26","author":"Gruenberger","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0490","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103139_b0495","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0500","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0505","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2026.103139_b0510","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","article-title":"A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer","volume":"27","author":"Hecht","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0515","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/annonc\/mdm607","article-title":"A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity","volume":"19","author":"Tol","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0520","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.1993.11.12.2386","article-title":"Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy","volume":"11","author":"Moertel","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0525","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1038\/bjc.1998.333","article-title":"Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer","volume":"77","author":"Peppercorn","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0530","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","article-title":"Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases","volume":"24","author":"Vauthey","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0535","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.sla.0000193603.26265.c3","article-title":"Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases","volume":"243","author":"Karoui","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0545","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1245\/s10434-011-2061-0","article-title":"A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases","volume":"19","author":"Lam","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0550","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/jso.25784","article-title":"Disappearing colorectal liver metastases: Strategies for the management of patients achieving a radiographic complete response after systemic chemotherapy","volume":"121","author":"Araujo","year":"2020","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0555","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2006.05.8727","article-title":"Complete response of colorectal liver metastases after chemotherapy: does it mean cure?","volume":"24","author":"Benoist","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0560","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/SLA.0b013e3181b0c6e4","article-title":"Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases","volume":"250","author":"Tanaka","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0565","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s11605-010-1348-y","article-title":"Disappearing colorectal liver metastases after chemotherapy: should we be concerned?","volume":"14","author":"van Vledder","year":"2010","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2025.103981","article-title":"Navigating Disappearing Liver Metastases in Colorectal Cancer: A Review of Surgical and Non-Surgical Approaches","volume":"49","author":"Valle","year":"2026","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ctrv.2026.103139_b0575","doi-asserted-by":"crossref","first-page":"761","DOI":"10.5306\/wjco.v11.i10.761","article-title":"Colorectal liver metastases: Current management and future perspectives","volume":"11","author":"Martin","year":"2020","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0580","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/tri.13471","article-title":"Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation - a retrospective study","volume":"32","author":"Smedman","year":"2019","journal-title":"Transpl Int"},{"key":"10.1016\/j.ctrv.2026.103139_b0585","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bmj.324.7341.813","article-title":"Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials","volume":"324","author":"Renehan","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2026.103139_b0590","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/jama.2013.285718","article-title":"Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial","volume":"311","author":"Primrose","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2026.103139_b0595","article-title":"Follow-up strategies for patients treated for non-metastatic colorectal cancer","volume":"11","author":"Jeffery","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2026.103139_b0600","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.surg.2013.04.021","article-title":"Post-treatment surveillance of patients with colorectal cancer with surgically treated liver metastases","volume":"154","author":"Hyder","year":"2013","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2026.103139_b0605","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/jama.2010.460","article-title":"Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006","volume":"303","author":"Dinan","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2026.103139_b0610","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMra072149","article-title":"Computed tomography\u2013an increasing source of radiation exposure","volume":"357","author":"Brenner","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103139_b0615","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bjc.6603219","article-title":"Intensive follow-up after liver resection for colorectal liver metastases: results of combined serial tumour marker estimations and computed tomography of the chest and abdomen - a prospective study","volume":"95","author":"Bhattacharjya","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103139_b0620","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12957-015-0738-8","article-title":"Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases","volume":"13","author":"Angelsen","year":"2015","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0625","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/bjs.10191","article-title":"Factors influencing recurrence following initial hepatectomy for colorectal liver metastases","volume":"103","author":"Hallet","year":"2016","journal-title":"Br J Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0630","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/archsurg.139.7.749","article-title":"Choice of surveillance after hepatectomy for colorectal metastases","volume":"139","author":"Metcalfe","year":"2004","journal-title":"Arch Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0635","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1245\/s10434-016-5388-8","article-title":"Posttreatment Surveillance in Patients with Prolonged Disease-Free Survival After Resection of Colorectal Liver Metastasis","volume":"23","author":"Galjart","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0640","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","article-title":"Actual 10-year survival after resection of colorectal liver metastases defines cure","volume":"25","author":"Tomlinson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0645","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1245\/s10434-008-9935-9","article-title":"Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity","volume":"15","author":"Vigan\u00f2","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0650","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1477-2574.2010.00155.x","article-title":"What defines \u201ccure\u201d after liver resection for colorectal metastases? Results after 10 years of follow-up","volume":"12","author":"Pulitan\u00f2","year":"2010","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ctrv.2026.103139_b0655","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.17021","article-title":"Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation","volume":"22","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ctrv.2026.103139_b0660","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2026.103139_b0665","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1158\/1078-0432.CCR-17-0510","article-title":"Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer","volume":"23","author":"Sch\u00f8ler","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103139_b0670","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf072","article-title":"Molecular prognostic factors for liver transplantation of unresectable metastatic colorectal cancer","volume":"112","author":"Moosavi","year":"2025","journal-title":"Br J Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0675","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jnci\/djab042","article-title":"BRAFV600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database","volume":"113","author":"Cohen","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103139_b0680","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2018.0996","article-title":"Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer","volume":"153","author":"Margonis","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0685","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2026.103139_b0690","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0695","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/cancers16050927","article-title":"Circulating Tumor DNA Profiling in Liver Transplant for Hepatocellular Carcinoma, Cholangiocarcinoma, and Colorectal Liver Metastases: A Programmatic Proof of Concept","volume":"16","author":"Hong","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103139_b0700","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/2159-8290.CD-17-0891","article-title":"Longitudinal liquid biopsy and mathematical modelling of clonal evolution forecast waiting time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial","volume":"8","author":"Khan","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103139_b0705","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fimmu.2026.1738295","article-title":"ctDNA guided management of POLE mutant GI malignancies promotes exceptional responses and prolonged survival to immunotherapy","volume":"Volume","author":"Mahmood","year":"2026","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.ctrv.2026.103139_b0710","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer","volume":"5","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0715","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/gutjnl-2014-308859","article-title":"Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery","volume":"65","author":"Reinert","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2026.103139_b0720","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103139_b0725","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103139_b0730","doi-asserted-by":"crossref","unstructured":"Wehrle CJ, Raj R, Aykun N, Orabi D, Stackhouse K, Chang J, et al. Circulating Tumor DNA in Colorectal Cancer Liver Metastasis: Analysis of Patients Receiving Liver Resection and Transplant. JCO Clin Cancer Inform 2023:e2300111. 10.1200\/CCI.23.00111.","DOI":"10.1200\/CCI.23.00111"},{"key":"10.1016\/j.ctrv.2026.103139_b0735","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/2159-8290.CD-17-0891","article-title":"Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial","volume":"8","author":"Khan","year":"2018","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.ctrv.2026.103139_b0740","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2026.103139_b0745","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ctrv.2026.103139_b0750","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3350\/cmh.2014.20.2.192","article-title":"Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation","volume":"20","author":"Lee","year":"2014","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103139_b0755","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103139_b0760","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1245\/s10434-023-13147-6","article-title":"The Current State of Liver Transplantation for Colorectal Liver Metastases in the United States: A Call for Standardized Reporting","volume":"30","author":"Sasaki","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103139_b0765","doi-asserted-by":"crossref","unstructured":"Kwong A, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, et al. OPTN\/SRTR 2018 Annual Data Report: Liver. Am J Transplant 2020;20 Suppl s1:193\u2013299. 10.1111\/ajt.15674.","DOI":"10.1111\/ajt.15674"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2026.103139_b0770","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/ajt.16494","article-title":"OPTN\/SRTR 2019 Annual Data Report: Liver","volume":"21","author":"Kwong","year":"2021","journal-title":"Am J Transplant"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2026.103139_b0775","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ajt.16978","article-title":"OPTN\/SRTR 2020 Annual Data Report: Liver","volume":"22","author":"Kwong","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ctrv.2026.103139_b0780","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.ajt.2023.02.006","article-title":"OPTN\/SRTR 2021 Annual Data Report: Liver","volume":"23","author":"Kwong","year":"2023","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.ctrv.2026.103139_b0785","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.ajt.2024.01.014","article-title":"OPTN\/SRTR 2022 Annual Data Report: Liver","volume":"24","author":"Kwong","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ctrv.2026.103139_b0790","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103139_b0795","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/LVT.0000000000000303","article-title":"The incidence of adverse outcome in donors after living donor liver transplantation: A meta-analysis of 60,829 donors","volume":"30","author":"Xiao","year":"2024","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.ctrv.2026.103139_b0800","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/apt.70434","article-title":"Waitlist and Post-Transplant Outcomes in Liver Transplantation for Alcohol-Associated Liver Disease: An Individual Patient Data Meta-Analysis","volume":"63","author":"Ho","year":"2026","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.ctrv.2026.103139_b0805","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2468-1253(19)30451-0","article-title":"Liver transplantation in patients with alcohol-related liver disease: current status and future directions","volume":"5","author":"Mathurin","year":"2020","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.ctrv.2026.103139_b0810","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jceh.2022.06.013","article-title":"Liver Transplantation in Alcohol-related Liver Disease and Alcohol-related Hepatitis","volume":"13","author":"Ntandja Wandji","year":"2023","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.ctrv.2026.103139_b0815","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1499-3872(14)60037-0","article-title":"Liver transplantation versus liver resection for hepatocellular carcinoma: a meta-analysis","volume":"13","author":"Xu","year":"2014","journal-title":"Hepatobiliary & Pancreatic Diseases International"},{"key":"10.1016\/j.ctrv.2026.103139_b0820","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3892\/ol.2026.15447","article-title":"Prognosis of liver transplantation and hepatectomy in patients with hepatocellular carcinoma meeting the Milan criteria: A systematic review and meta-analysis","volume":"31","author":"Wang","year":"2026","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctrv.2026.103139_b0825","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/MOT.0000000000000069","article-title":"Liver transplantation: immunosuppression and oncology","volume":"19","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2014","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.ctrv.2026.103139_b0830","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/SLA.0000000000004280","article-title":"mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors","volume":"272","author":"Schnitzbauer","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2026.103139_b0835","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12072-023-10537-6","article-title":"Hepatocellular carcinoma (HCC) tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) tumor microenvironment","volume":"18","author":"Santagata","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ctrv.2026.103139_b0840","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1158\/0008-5472.CAN-23-0193","article-title":"Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer","volume":"83","author":"Chen","year":"2023","journal-title":"Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:08:58Z","timestamp":1778292538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":168,"alternative-id":["S0305737226000538"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103139","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding the therapeutic Frontier: Liver transplantation for unresectable colorectal liver metastases","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103139"}}